Levetiracetam Viatris

Levetiracetam, the active ingredient in Levetiracetam Viatris, is an antiepileptic presented as a sterile injection for intravenous use. It is indicated for the treatment of partial‑onset seizures, myoclonic seizures, and generalized tonic‑clonic seizures in patients who require rapid and reliable seizure control.

GNH USA supplies Levetiracetam Viatris as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, and supporting global procurement for health‑care institutions seeking EU‑approved injectable antiepileptic medicines and ensuring compliance with local regulatory requirements.

Levetiracetam is an antiepileptic medication that modulates neuronal excitability to control seizure activity.

- Partial‑onset seizures: reduces frequency and severity of focal seizures. - Myoclonic seizures: decreases occurrence of sudden muscle jerks. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes. - Adjunctive therapy for epilepsy: used alongside other antiepileptics to improve overall seizure control.

Levetiracetam may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of lightheadedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Irritability: increased emotional sensitivity or agitation. - Nausea: upset stomach with possible vomiting. - Somnolence: drowsiness or sleepiness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Blood dyscrasias: neutropenia, leukopenia, or thrombocytopenia. - Mood changes: depression, suicidal thoughts, or aggressive behavior. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When using Levetiracetam injection, clinicians should consider several precautionary measures to ensure patient safety and product integrity.

- Renal impairment: adjust dosing and monitor renal function. - History of psychiatric disorders: observe for mood changes or aggression. - Concomitant CNS depressants: assess for enhanced sedation. - Pregnancy: evaluate risk‑benefit as safety data are limited. - Monitoring: perform regular blood counts and liver function tests. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease levetiracetam exposure. - Phenytoin: may lower levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: potential for increased adverse effects. - Sedative agents (benzodiazepines, opioids): enhanced CNS depression. - Alcohol: may intensify dizziness and somnolence.